150.00 rub.
Buy article

Genetic parallels of heart failure and chronic obstructive pulmonary disease

Hazova E. V., Bulashova O. V., Malkova M. I.
Federal State Budget Educational Institution of Higher Education, "Kazan State Medical University" of the Ministry of Health of the Russian Federation, Butlerova 49, Kazan 420012

Keywords: CHF, chronic obstructive pulmonary disease, A DR B2 gene polymorphism, comorbidity, cardio-respiratory association

DOI: 10.18087/rhfj.2017.2.2299

Comorbidity of cardiovascular and respiratory diseases is a serious problem due to unfavorable prognosis for this category of patients. Predisposition to the cardiorespiratory association is based on a pathological genotype that forms an unfavorable genetic background. This article focuses on genetic aspects of the clinical course of CHF and chronic obstructive pulmonary disease (COPD) in relation with β2-adrenoceptor (ADRB2) gene polymorphisms affecting the β2-adrenoceptor function. A high incidence of the ADRB2 gene Glu27Glu genotype (0.30) was observed in CHF patients from certain regions compared to groups without cardiovascular diseases (0.15) (р<0.05) whereas other studies did not report any relationship of this polymorphism with the risk or prognosis for CHF. Several studies have reported that allele variants of the ADRB2 gene at positions 16 and 27 may influence the lung function or predisposition to COPD. The genotype distribution differed in Caucasian and Asian populations for both positions 16 and 27 (р<0.05 except for the Arg16Gly genotype). A cohort study of patients with COPD of different severity discovered an association of the Arg16 allele and the Arg16/Gln27 haplotype with a reduced bronchodilatory response. Considering inconsistent results of studies presented in the analyzed literature, targeted search for genetic markers for development of the cardiorespiratory association should be performed with due account of population characteristics in order to individualize this approach in selecting a drug therapy to prolong quality life of patients.
  1. Фомин И. В. Артериальная гипертония в Российской Федерации – последние десять лет. Что дальше? Сердце: журнал для практикующих врачей. 2007;6(3):120–3 [Fomin I. V. Arterial`naya gipertoniya v Rossijskoj Federaczii – poslednie desyat` let. Chto dal`she? Serdcze: zhurnal dlya praktikuyushhix vrachej. 2007;6(3):120–3].
  2. Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG, McMurray JJV. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail. 2009;11(2):130–9. DOI:10.1093/eurjhf/hfn013.
  3. Apostolovic S, Jankovic-Tomasevic R, Salinger-Martinovic S, Djordjevic-Radojkovic D, Stanojevic D, Pavlovic M et al. Frequency and significance of unrecognized chronic obstructive pulmonary disease in elderly patients with stable heart failure. Aging Clinical and Experimental Research. 2011;(5–6). DOI:10.3275/7291.
  4. Valk MJ, Broekhuizen BD, Mosterd A, Zuithoff NP, Hoes AW, Rutten FH. COPD in patients with stable heart failure in the primary care setting. Int J Chron Obstruct Pulmon Dis. 2015;10:1219–24. DOI:10.2147/COPD.S77085.
  5. Brodde O-E. Beta1- and beta2-adrenoceptor polymorphisms and cardiovascular diseases. Fundam Clin Pharmacol. 2008;22(2):107–25. DOI:10.1111/j.1472-8206.2007.00557.x.
  6. Reihsaus E, Innis M, MacIntyre N, Liggett SB. Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects. Am J Respir Cell Mol Biol. 1993;8(3):334–9. DOI:10.1165/ajrcmb/8.3.334.
  7. Liggett SB. The pharmacogenetics of beta2-adrenergic receptors: relevance to asthma. J Allergy Clin Immunol. 2000;105(2 Pt 2):S487-492.
  8. Kaye DM, Smirk B, Williams C, Jennings G, Esler M, Holst D. Beta-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure. Pharmacogenetics. 2003;13(7):379–82. DOI:10.1097/01.fpc.0000054104.48725.15.
  9. Pereira SB, Velloso MWM, Chermont S, Quintão MMP, Nunes Abdhala R, Giro C et al. β-adrenergic receptor polymorphisms in susceptibility, response to treatment and prognosis in heart failure: implication of ethnicity. Mol Med Rep. 2013;7(1):259–65. DOI:10.3892/mmr.2012.1120.
  10. Арутюнов Г. П., Гончарова Л. Н., Постнов А. Ю. Генетические предикторы развития хронической сердечной недостаточности у больных артериальной гипертонией в популяциях Республики Мордовия. Журнал Сердечная Недостаточность. 2012;13(6):355–64 [Arutyunov G. P., Goncharova L. N., Postnov A. Yu. Geneticheskie prediktory` razvitiya xronicheskoj serdechnoj nedostatochnosti u bol`ny`x arterial`noj gipertoniej v populyacziyax Respubliki Mordoviya. Zhurnal Serdechnaya Nedostatochnost`. 2012;13(6):355–64].
  11. Хазова Е. В., Булашова О. В., Газизянова В. М., Кравцова О. А., Малкова М. И. Улучшают ли β-адреноблокаторы прогноз больных ХСН: клинико-генетическое исследование в регионе Республика Татарстан. Журнал Сердечная Недостаточность. 2015;16(2):106–10 [Xazova E. V., Bulashova O. V., Gazizyanova V. M., Kravczova O. A., Malkova M. I. Uluchshayut li β-adrenoblokatory` prognoz bol`ny`x XSN: kliniko-geneticheskoe issledovanie v regione Respublika Tatarstan. Zhurnal Serdechnaya Nedostatochnost`. 2015;16(2):106–10].
  12. Liggett SB, Wagoner LE, Craft LL, Hornung RW, Hoit BD, McIntosh TC et al. The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. J Clin Invest. 1998;102(8):1534–9. DOI:10.1172/JCI4059.
  13. Yancy CW, Fowler MB, Colucci WS, Gilbert EM, Bristow MR, Cohn JN et al. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med. 2001;344(18):1358–65. DOI:10.1056/NEJM200105033441803.
  14. Jaillon P, Simon T. [Genetic polymorphism of beta-adrenergic receptors and mortality in ischemic heart disease]. Therapie. 2007;62(1):1–7. DOI:10.2515/therapie:2007010.
  15. Leineweber K, Tenderich G, Wolf C, Wagner S, Zittermann A, Elter-Schulz M et al. Is there a role of the Thr164Ile-beta(2)-adrenoceptor polymorphism for the outcome of chronic heart failure? Basic Res Cardiol. 2006;101(6):479–84. DOI:10.1007/s00395-006-0601-8.
  16. Covolo L, Gelatti U, Metra M, Nodari S, Piccichè A, Pezzali N et al. Role of beta1- and beta2-adrenoceptor polymorphisms in heart failure: a case-control study. Eur Heart J. 2004;25(17):1534–41. DOI:10.1016/j.ehj.2004.06.015.
  17. Forleo C, Resta N, Sorrentino S, Guida P, Manghisi A, De Luca V et al. Association of beta-adrenergic receptor polymorphisms and progression to heart failure in patients with idiopathic dilated cardiomyopathy. Am J Med. 2004;117(7):451–8. DOI:10.1016/j.amjmed.2004.04.012.
  18. Moraga F, Troncoso R , Mellado R , Díaz-Araya G, Vukasovic JL, Greig D et al. [Interactions between beta1 and beta2 adrenergic receptor polymorphisms as risk factors for chronic heart failure]. Rev Med Chil. 2008;136(11):1371–80.
  19. Wagoner LE, Craft LL, Singh B, Suresh DP, Zengel PW, McGuire N et al. Polymorphisms of the beta(2)-adrenergic receptor determine exercise capacity in patients with heart failure. Circ Res. 2000;86(8):834–40.
  20. Kim K-M, Murray MD, Tu W, Robarge J, Ding Y, Brater DC et al. Pharmacogenetics and healthcare outcomes in patients with chronic heart failure. Eur J Clin Pharmacol. 2012;68(11):1483–91. DOI:10.1007/s00228-012-1280-z.
  21. Lobmeyer MT, Gong Y, Terra SG, Beitelshees AL, Langaee TY, Pauly DF et al. Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure. Pharmacogenet Genomics. 2007;17(4):277–82. DOI:10.1097/FPC.0b013e3280105245.
  22. Ho LI, Harn HJ, Chen CJ, Tsai NM. Polymorphism of the beta(2)-adrenoceptor in COPD in Chinese subjects. Chest. 2001;120(5):1493–9.
  23. Vacca G, Schwabe K, Dück R , Hlawa H-P, Westphal A, Pabst S et al. Polymorphisms of the beta2-adrenoreceptor gene in chronic obstructive pulmonary disease. Ther Adv Respir Dis. 2009;3(1):3–10. DOI:10.1177/1753465809102553.
  24. Kim WJ, Oh Y-M, Sung J, Kim T-H, Huh JW, Jung H et al. Lung function response to 12-week treatment with combined inhalation of long-acting beta2 agonist and glucocorticoid according to ADRB2 polymorphism in patients with chronic obstructive pulmonary disease. Lung. 2008;186(6):381–6. DOI:10.1007/s00408-008-9103-9.
  25. Umeda N, Yoshikawa T, Kanazawa H, Hirata K, Fujimoto S. Association of beta2-adrenoreceptor genotypes with bronchodilatory effect of tiotropium in COPD. Respirology. 2008;13(3):346–52. DOI:10.1111/j.1440-1843.2008.01259.x.
  26. Mokry M, Joppa P, Slaba E, Zidzik J, Habalova V, Kluchova Z et al. Beta2-adrenergic receptor haplotype and bronchodilator response to salbutamol in patients with acute exacerbations of COPD. Med Sci Monit. 2008;14(8):CR392-398.
  27. Joos L, Weir TD, Connett JE, Anthonisen NR , Woods R , Paré PD et al. Polymorphisms in the beta2 adrenergic receptor and bronchodilator response, bronchial hyperresponsiveness, and rate of decline in lung function in smokers. Thorax. 2003;58(8):703–7.
  28. Niu L-M, Liang Y, Xu M, Zhang Y-Y, Zhang Y, He B. Effect of polymorphisms in the β2-adrenergic receptor on the susceptibility and pulmonary function of patients with chronic obstructive pulmonary disease: a meta analysis. Chin Med J. 2012;125(12):2213–8.
  29. Hizawa N, Makita H, Nasuhara Y, Betsuyaku T, Itoh Y, Nagai K et al. Beta2-adrenergic receptor genetic polymorphisms and short-term bronchodilator responses in patients with COPD. Chest. 2007;132(5):1485–92. DOI:10.1378/chest.07-1103.
  30. Bleecker ER , Meyers DA, Bailey WC, Sims A-M, Bujac SR, Goldman M et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPD. Chest. 2012;142(2):320–8. DOI:10.1378/chest.11-1655.
  31. Мустафина М. Х., Цветкова О. А. Фармакогенетический эффект полиморфизма гена ADRB2 на терапию хронической обструктивной болезни легких. Пульмонология. 2013;(3):21–4 [Mustafina M. X., Czvetkova O. A. Farmakogeneticheskij e`ffekt polimorfizma gena ADRB2 na terapiyu xronicheskoj obstruktivnoj bolezni legkix. Pul`monologiya. 2013;(3):21–4].
Hazova E. V., Bulashova O. V., Malkova M. I. Genetic parallels of heart failure and chronic obstructive pulmonary disease. Russian Heart Failure Journal. 2017;18 (2):138–143

To access this material please log in or register

Register Authorize
Ru En